Zobrazeno 1 - 10
of 775
pro vyhledávání: '"Michael B. Atkins"'
Autor:
Kelly Gaudian, Min Jung Koh, Min Ji Koh, Peter Jermain, Irfan Khan, Diya Kallam, Zach Lee, Ryan R. Collins, Zoya Zwart, Malika Danner, Alan Zwart, Deepak Kumar, Michael B. Atkins, Simeng Suy, Sean P. Collins
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionPrior studies suggest lymphopenia following radiation therapy may impact toxicity and cancer control. Chronic radiation-related lymphopenia (RRL) has been noted in prostate cancer patients treated with conventionally fractionated pelvic r
Externí odkaz:
https://doaj.org/article/a84efa618455491090554a44fc51390f
Autor:
Thomas Powles, Laurence Albiges, David F McDermott, Michael B Atkins, Toni K Choueiri, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Martin H Voss, Hans J Hammers, Chung-Han Lee, Robert J Motzer, Yoshihiko Tomita, Nizar M Tannir, Meredith M Regan, Charlene M Mantia, Lisa Rosenblatt, Opeyemi A Jegede
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Immunotherapy can be associated with prolonged disease control even after cessation of treatment without the need for further cancer-directed therapy. Treatment-related adverse events (TRAEs) can also persist after discontinuation of thera
Externí odkaz:
https://doaj.org/article/e929a9c890ec467cac7b04eb3f99fada
Autor:
Michael Hurwitz, Mark Stein, Jeffrey Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Meredith M Regan, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Paul J Catalano
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background As part of a partitioned survival analysis, treatment-free survival (TFS) can characterize the overall survival time patients spend between the cessation of immunotherapy and the start of subsequent therapy; both with and without toxicity.
Externí odkaz:
https://doaj.org/article/23ac543db705415f93126b90c7cd9853
Autor:
Gino K. In, Jennifer R. Ribeiro, Jun Yin, Joanne Xiu, Matias A. Bustos, Fumito Ito, Frances Chow, Gabriel Zada, Lindsay Hwang, April K. S. Salama, Soo J. Park, Justin C. Moser, Sourat Darabi, Evidio Domingo-Musibay, Maria L. Ascierto, Kim Margolin, Jose Lutzky, Geoffrey T. Gibney, Michael B. Atkins, Benjamin Izar, Dave S. B. Hoon, Ari M. VanderWalde
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-10 (2023)
Abstract Melanoma brain metastases (MBM) are clinically challenging to treat and exhibit variable responses to immune checkpoint therapies. Prior research suggests that MBM exhibit poor tumor immune responses and are enriched in oxidative phosphoryla
Externí odkaz:
https://doaj.org/article/32efd05519e741b4bbdba359b3adab39
Autor:
Michael Hurwitz, Elizabeth Plimack, Jeffrey Sosman, Sabina Signoretti, David F McDermott, Michael B Atkins, Naomi B Haas, Hans Hammers, Nicholas Schindler, Opeyemi A Jegede, Catherine J Wu, David Braun, Miya Hugaboom, Kelly Street, Neil Ruthen, Lena Wirth
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/8268242ef3d34b96ae74e8d3558065da
Autor:
Samir Gupta, Michael B Atkins, Neil J Shah, Jacob Zaemes, Shaked Lev Ari, Yili Zhang, Adil Alaoui, Subha Madhavan, Peter McGarvey
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a4c1b501eb1d4b51a05770744fdfed2a
Autor:
Samir Gupta, Michael B Atkins, Meredith Regan, Neil J Shah, Jacob Zaemes, Opeyemi A Jegede, Shaked Lev Ari, Lauren Pascual, Natali Arias-Orozco, Brittany Sinclaire, Alexandra DellaPia, Rachel A Zemel, Yili Zhang, Adil Alaoui, Andrew Ip
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/543f662ef85345d892a18d4460b414d0
Autor:
Michael B Atkins, Neil J Shah, Jacob Zaemes, Andrew Pecora, Shaked Lev Ari, Lauren Pascual, Brittany Sinclaire, Alexandra DellaPia, Rachel A Zemel, Adil Alaoui, Andrew Ip, Deniz Ozisik, Ming Tan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/330e36ff912446ba91242d45a6d6e317
Autor:
Douglas B. Johnson, Michael B. Atkins, Cassandra Hennessy, Trisha Wise-Draper, Hannah Heilman, Joy Awosika, Ziad Bakouny, Chris Labaki, Renee Maria Saliby, Clara Hwang, Sunny R. K. Singh, Nino Balanchivadze, Christopher R. Friese, Leslie A. Fecher, James J. Yoon, Brandon Hayes-Lattin, Mehmet A. Bilen, Cecilia A. Castellano, Gary H. Lyman, Lisa Tachiki, Sumit A. Shah, Michael J. Glover, Daniel B. Flora, Elizabeth Wulff-Burchfield, Anup Kasi, Saqib H. Abbasi, Dimitrios Farmakiotis, Kendra Viera, Elizabeth J. Klein, Lisa B. Weissman, Chinmay Jani, Matthew Puc, Catherine C. Fahey, Daniel Y. Reuben, Sanjay Mishra, Alicia Beeghly-Fadiel, Benjamin French, Jeremy L. Warner, COVID-19 and Cancer Consortium
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Introduction COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 s
Externí odkaz:
https://doaj.org/article/69fb2be87d9e4455bca96362eb3128f6
Autor:
Tian Zhang, Patrick M Forde, Elad Sharon, Scot Ebbinghaus, Michael B Atkins, Mark Stewart, Ryan J Sullivan, Elizabeth Barksdale, Wendy Selig, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
With multiple PD-(L)1 inhibitors approved across dozens of indications by the US Food and Drug Administration, the number of patients exposed to these agents in adjuvant, first-line metastatic, second-line metastatic, and refractory treatment setting
Externí odkaz:
https://doaj.org/article/48319baa5c5a4d68b9c0d564b37e5e92